Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

ABCG2 expression, function, and promoter methylation in human multiple myeloma.

Authors: Turner, JG  Gump, JL  Zhang, C  Cook, JM  Marchion, D  Hazlehurst, L  Munster, P  Schell, MJ  Dalton, WS  Sullivan, DM 
Citation: Turner JG, etal., Blood. 2006 Dec 1;108(12):3881-9. Epub 2006 Aug 17.
Pubmed: (View Article at PubMed) PMID:16917002
DOI: Full-text: DOI:10.1182/blood-2005-10-009084

We investigated the role of the breast cancer resistance protein (BCRP/ABCG2) in drug resistance in multiple myeloma (MM). Human MM cell lines, and MM patient plasma cells isolated from bone marrow, were evaluated for ABCG2 mRNA expression by quantitative polymerase chain reaction (PCR) and ABCG2 protein, by Western blot analysis, immunofluorescence microscopy, and flow cytometry. ABCG2 function was determined by measuring topotecan and doxorubicin efflux using flow cytometry, in the presence and absence of the specific ABCG2 inhibitor, tryprostatin A. The methylation of the ABCG2 promoter was determined using bisulfite sequencing. We found that ABCG2 expression in myeloma cell lines increased after exposure to topotecan and doxorubicin, and was greater in logphase cells when compared with quiescent cells. Myeloma patients treated with topotecan had an increase in ABCG2 mRNA and protein expression after treatment with topotecan, and at relapse. Expression of ABCG2 is regulated, at least in part, by promoter methylation both in cell lines and in patient plasma cells. Demethylation of the promoter increased ABCG2 mRNA and protein expression. These findings suggest that ABCG2 is expressed and functional in human myeloma cells, regulated by promoter methylation, affected by cell density, up-regulated in response to chemotherapy, and may contribute to intrinsic drug resistance.


Disease Annotations
Objects Annotated

Additional Information

CRRD Object Information
CRRD ID: 11081144
Created: 2016-05-26
Species: All species
Last Modified: 2016-05-26
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.